LATIFY Phase III trial

• AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial - Dec 22 () - AstraZeneca said on Monday that a late‑stage trial testing ​Imfinzi in combination with ceralasertib failed ‌to improve overall survival versus standard treatments in ‌patients with previously treated advanced non‑small cell lun